MELINTA THERAPEUTICS, INC. /NEW/ - FORM 8-K - EX-99.2 - EXHIBIT 99.2 - April 14, 2020

Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - MELINTA THERAPEUTICS, INC. /NEW/ex991confirmationorderwith.htm
8-K - 8-K-CONFIRMATION ORDER - MELINTA THERAPEUTICS, INC. /NEW/a8-kxconfirmationorder.htm





IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE
    
MELINTA THERAPEUTICS, INC., et al., 1                                Case No. 19-12748 (LSS)
Debtors                                         Reporting Period: 2/1/2019-2/29/2020
MOR-3
DEBTORS COMBINED CONDENSED BALANCE SHEETS 1 
 Period Ending
PETITION DATE 2
 
2/29/2020
ASSETS
 
 
 
Current Assets
 
 
 
  Cash And Cash Equivalents
 $ 52,507,161
 
 $ 52,072,226
  Accounts Receivable
          7,343,412
 
            9,530,100
  Tax Credit Receivable
             127,279
 
               127,279
  Other Receivables
          6,149,301
 
            4,643,419
  Inventory
        34,607,415
 
          33,343,353
  Prepaid And Other Current Assets
        14,091,087
 
          11,704,443
    Total Current Assets
 $ 114,825,654
 
 $ 111,420,820
 
 
 
 
Long Term Assets
 
 
 
Fixed Assets, Gross
 $ 2,490,656
 
 $ 2,490,656
Accumulated Depreciation
        (1,767,729)
 
          (1,833,606)
Fixed Assets, Net
 $ 722,927
 
 $ 657,050
Intangible Assets
        39,366,283
 
          38,772,127
Other Assets
        46,989,118
 
          47,693,659
Total Long Term Assets
 $ 87,078,328
 
 $ 87,122,836
 
 
 
 
Total Assets
 $ 201,903,982
 
 $ 198,543,656
 
 
 
 
LIABILITIES AND STOCKHOLDERS' DEFICIT
 
 
 
Current Liabilities
 
 
 
  Accounts Payable
0
 
 $ 2,398,442
  Accrued Expenses
             798,788
 
            9,088,749
  Accrued Interest On Note Payable
          3,763,524
 
            6,613,602
  Other Current Liabilities
          1,931,780
 
            1,931,780
  Preferred Stock Warrants
0
 
0
Total Current Liabilities
 $ 6,494,092
 
 $ 20,032,572
 
 
 
 
Long-Term Liabilities
 
 
 
  Notes Payable, Net Of Current
 $ 92,272,610
 
 $ 88,926,081
  Convertible Notes
0
 
0
  Liability For Potential Royalties
             196,152
 
               126,998
  Other Long-Term Liabilities
          2,898,733
 
            2,904,609
Total Long-Term Liabilities
 $ 95,367,496
 
 $ 91,957,687
 
 
 
 
Liabilities Subject To Compromise
 $ 173,833,171
 
 $ 190,647,945
 
 
 
 
Stockholders' Deficit
 
 
 
  Common Stock
 $ 13,751
 
 $ 13,751
  Additional Paid-In Capital
      939,864,708
 
        939,912,934
  Accumulated Deficit
    (721,784,980)
 
   (1,028,085,830)
  Current Year Loss
    (291,884,257)
 
        (15,935,404)
Total Stockholders' Deficit
 $ (73,790,777)
 
 $ (104,094,549)
 
 
 
 
Total Liabilities And Stockholders' Deficit
 $ 201,903,982
 
 $ 198,543,656
Notes:
1.
Melinta Subsidiary Corp. (case number 19-12751) assumed to be the operating entity and Melinta Therapeutics, Inc. (case number 19-12748), Cempra Pharmaceuticals, Inc. (case number 19-12749), CEM-102 Pharmaceuticals, Inc. (case number 19-12750), Rempex Pharmaceuticals, Inc. (case number 19-12752), and Targanta Therapeutics Corporation (case number 19-12753) assumed to be dormant entities.
2.
Petition Date balance sheet reflects additional pre-petition entries to write-down to $0 fair value of the future royalty liability to The Medicines Company.

Page 1

MELINTA THERAPEUTICS, INC. /NEW/ Reports